Arca BioPharma hopeful about personalized beta blocker

07/28/2008 | American City Business Journals

Arca BioPharma is inching closer to launching bucindolol, an experimental beta blocker that would be the first genetically targeted heart-failure drug. The biotech firm intends to file this week for FDA approval of the drug along with a genetic test being developed by partner Lab Corp.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI